{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TAS-102",
    "query": {
      "intervention": "TAS-102"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 73,
    "total_pages": 8,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TAS-102&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T01:17:32.392Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03762161",
      "title": "A Phase II Study of Lonsurf (TAS-102) in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "TAS 102",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rahul Parikh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2019-01-03",
      "completion_date": "2024-01",
      "has_results": false,
      "last_update_posted_date": "2022-03-10",
      "last_synced_at": "2026-09-03T01:17:32.392Z",
      "location_count": 2,
      "location_summary": "Fairway, Kansas • Kansas City, Kansas",
      "locations": [
        {
          "city": "Fairway",
          "state": "Kansas"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03762161"
    },
    {
      "nct_id": "NCT02602327",
      "title": "Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colon Cancer",
        "Rectal Cancer",
        "Liver Metastases"
      ],
      "interventions": [
        {
          "name": "Tas-102",
          "type": "DRUG"
        },
        {
          "name": "SIR-Sphere",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2017-01-09",
      "completion_date": "2021-08-31",
      "has_results": false,
      "last_update_posted_date": "2022-08-01",
      "last_synced_at": "2026-09-03T01:17:32.392Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02602327"
    },
    {
      "nct_id": "NCT05029882",
      "title": "Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Advanced Solid Tumors",
        "Gastroesophageal Adenocarcinoma",
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "ABBV-400",
          "type": "DRUG"
        },
        {
          "name": "Trifluridine/Tipiracil",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 520,
      "start_date": "2021-10-13",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2025-10-29",
      "last_synced_at": "2026-09-03T01:17:32.392Z",
      "location_count": 18,
      "location_summary": "Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 13 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Fort Wayne",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05029882"
    },
    {
      "nct_id": "NCT01867879",
      "title": "Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors (Excluding Breast Cancer)"
      ],
      "interventions": [
        {
          "name": "TAS-102",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Taiho Oncology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2013-06",
      "completion_date": "2015-04",
      "has_results": false,
      "last_update_posted_date": "2024-09-05",
      "last_synced_at": "2026-09-03T01:17:32.392Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01867879"
    },
    {
      "nct_id": "NCT06699836",
      "title": "The Phase-2 CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen Trial (CLOVER)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Colorectal Cancer (mCRC)"
      ],
      "interventions": [
        {
          "name": "350 mg leronlimab",
          "type": "DRUG"
        },
        {
          "name": "700 mg leronlimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CytoDyn, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 66,
      "start_date": "2025-06-16",
      "completion_date": "2028-03",
      "has_results": false,
      "last_update_posted_date": "2026-05-18",
      "last_synced_at": "2026-09-03T01:17:32.392Z",
      "location_count": 7,
      "location_summary": "Irvine, California • San Francisco, California • Washington D.C., District of Columbia + 4 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06699836"
    },
    {
      "nct_id": "NCT05731947",
      "title": "Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Revumenib",
          "type": "DRUG"
        },
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Syndax Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2023-04-04",
      "completion_date": "2025-06-30",
      "has_results": true,
      "last_update_posted_date": "2026-07-06",
      "last_synced_at": "2026-09-03T01:17:32.392Z",
      "location_count": 6,
      "location_summary": "Scottsdale, Arizona • Boston, Massachusetts • Manhattan, New York + 3 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Manhattan",
          "state": "New York"
        },
        {
          "city": "Canton",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05731947"
    },
    {
      "nct_id": "NCT04393298",
      "title": "A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "ginisortamab",
          "type": "DRUG"
        },
        {
          "name": "trifluridine/tipiracil",
          "type": "DRUG"
        },
        {
          "name": "mFOLFOX6",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UCB Biopharma SRL",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 93,
      "start_date": "2020-07-09",
      "completion_date": "2024-04-11",
      "has_results": true,
      "last_update_posted_date": "2025-05-29",
      "last_synced_at": "2026-09-03T01:17:32.392Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Charleston, South Carolina • Houston, Texas",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04393298"
    },
    {
      "nct_id": "NCT05848739",
      "title": "A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colon Cancer",
        "Metastatic Colon Cancer"
      ],
      "interventions": [
        {
          "name": "ST316",
          "type": "DRUG"
        },
        {
          "name": "FOLFIRI regimen & bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Fruquintinib",
          "type": "DRUG"
        },
        {
          "name": "Lonsurf & bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sapience Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 130,
      "start_date": "2023-06-05",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-22",
      "last_synced_at": "2026-09-03T01:17:32.392Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 8 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05848739"
    },
    {
      "nct_id": "NCT03368963",
      "title": "TAS102 in Combination With NAL-IRI in Advanced GI Cancers",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Adenocarcinoma",
        "Gastric Adenocarcinoma",
        "Metastatic Pancreatic Adenocarcinoma",
        "Non-Resectable Cholangiocarcinoma",
        "Stage IV Colorectal Cancer",
        "Stage IV Gastric Cancer",
        "Stage IV Pancreatic Cancer",
        "Stage IVA Colorectal Cancer",
        "Stage IVB Colorectal Cancer",
        "Stage III Colorectal Cancer",
        "Stage III Gastric Cancer",
        "Stage III Pancreatic Cancer",
        "Unresectable Digestive System Adenocarcinoma",
        "Unresectable Pancreatic Carcinoma"
      ],
      "interventions": [
        {
          "name": "Nanoliposomal Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Trifluridine and Tipiracil Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2018-01-30",
      "completion_date": "2025-11-28",
      "has_results": false,
      "last_update_posted_date": "2025-01-07",
      "last_synced_at": "2026-09-03T01:17:32.392Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03368963"
    },
    {
      "nct_id": "NCT05719558",
      "title": "A Study of ASP1002 in Adults for Treatment of Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "ASP1002",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Trifluridine-Tipiracil",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Ramucirumab",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 798,
      "start_date": "2023-03-13",
      "completion_date": "2030-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-23",
      "last_synced_at": "2026-09-03T01:17:32.392Z",
      "location_count": 15,
      "location_summary": "New Haven, Connecticut • Plainville, Connecticut • Gainesville, Florida + 11 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Plainville",
          "state": "Connecticut"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05719558"
    }
  ]
}